Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib and Amivantamab in Advanced Non-Small Cell Lung Cancer (Chrysalis-2)
NCT04077463Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2019
- Primary completion
- Feb 2027
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Bispecific Antibodies
- Countries
- 10
01
Overview
Phase 1, open-label trial of lazertinib and amivantamab in non-small cell lung cancer (NSCLC) (9 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 21 days, Overall Response Rate up to 2.5 years and 3 more. Started Sep 2019; status: active, not recruiting.
02
Drugs
lazertinibamivantamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04077463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04077463.